Experiencia en el tratamiento de tumores hepáticos mediante radioembolización con 90Y-microesferas de resina

  1. Soria-Merino, Mar 1
  2. Romero-Otero, Mónica 1
  3. Maestre-Cutillas, Roberto 1
  4. Carrero-Vásquez, Viviana 2
  5. Cánoves-Llombart, Adela 2
  6. Alamán-Sánchez, Carlos 3
  7. Rodríguez-Parra, Héctor 2
  1. 1 Unidad de Radiofarmacia. Hospital Clínico Universitario de Valencia.
  2. 2 Sección de Medicina Nuclear. Hospital Clínico Universitario de Valencia.
  3. 3 Servicio de Radiofísica y Protección Radiológica. Hospital Clínico Universitario de Valencia.
Mostra les afiliacions +
Revista:
Ars pharmaceutica

ISSN: 2340-9894,  0004-2927

Any de publicació: 2020

Volum: 61

Número: 4

Pàgines: 239-244

Tipus: Article

DOI: 10.30827/ARS.V61I4.15642 DIALNET GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: Ars pharmaceutica

Resum

Introduction: Transarterial radioembolization (TARE) is an alternative therapy for the treatment of unresectable liver tumors. Method: Retrospective and descriptive study in 27 patients undergoing TARE with Ytrio-90-loaded resin microspheres. Baseline, demographic and clinical characteristics were studied, and overall survival at 18 months was analyzed using the Kaplan-Meier method. Results: Age ranged between 52-85 years, and 81% of patients were men. 78% presented primary liver tumors, highlighting hepatocellular carcinoma BCLC (Barcelona Clinic Liver Cancer) stage B (HCC BCLC B) (44%). The origin of the most frequent secondary liver tumor was colorectal adenocarcinoma. The ECOG (Eastern Cooperative Oncology Group) was 0 for 78% of the patients and the antecedents were alcoholism (41%) and hepatitis C (56%). The average administered activity was 1.8 GBq. 34% received more than one previous treatment: surgical resection (11%), transarterial embolization or chemoembolization (48%), radiofrequency ablation (22%) or multi-kinase inhibitors (15%). 33% received subsequent treatment with multi-kinase inhibitors. The overall survival at 18 months was 58.9%. In patients with HCC BCLC B, the median survival was 15.6 months. Conclusion: The survival results are in line with those of other studies, although there are differences in some of the variables. It is necessary to have more patients and follow-up time to analyze its influence on survival.

Referències bibliogràfiques

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492.
  • Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology. 2020. doi: 10.1053/j.gastro.2020.02.068.
  • London WT, Petrick JL, McGlynn KA. Liver Cancer. En: Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, editores. Cancer Epidemiology and Prevention. 4ª ed. New York, Oxford University Press, 2018, p. 635-60. ISBN: 9780190238667.
  • Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007;5(8):938-45. doi: 10.1016/j.cgh.2007.02.039.
  • N’Kontchou G, Paries J, Htar MTT, Ganne–Carrie N, Costentin L, Grando–Lemaire V, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4(8):1062-8. doi: 10.1016/j.cgh.2006.05.013.
  • Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463-72. doi: 10.1053/gast.1997.v112.pm9024300.
  • Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. The Lancet. 2005;366(9493):1303-14. doi: 10.1016/S0140-6736(05)67530-7.
  • Doherty GM. Current diagnosis & treatment: surgery: Lange Medical Books/McGraw-Hill; 2010. 1312 p. ISSN: 9780071792127.
  • Türk G, Eldem G, Kılıçkap S, Bozkurt FM, Salancı BV, Çil BE, et al. Outcomes of radioembolization in patients with chemorefractory colorectal cancer liver metastasis: A single-center experience.
  • J gastrointes cancer. 2019;50(2):236-43. doi: 10.1007/s12029-018-0053-z.
  • EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019.
  • Mikell JK, Dewaraja YK, Owen D, editores. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Onco. 2020;30(1): 68-76. doi: 10.1016/j.semradonc.2019.08.005.
  • Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393. doi: 10.1007/s00259-011-1812-2.
  • Lau WY, Teoh YL, Win KM, Lee R-C, De Villa VH, Kim YHJ, et al. Current role of selective internal radiation with yttrium-90 in liver tumors. Future Oncol. 2016;12(9):1193-204. doi: 10.2217/fon-2016-0035.
  • Rodríguez-Fraile M, Iñarrairaegui M. Radioembolización de tumores hepáticos con 90Y-microesferas. Rev Esp Med Nucl Imagen Mol. 2015;34(4):244-57. doi: 10.1016/j.remn.2015.03.004.
  • Paprottka K, Schoeppe F, Ingrisch M, Rübenthaler J, Sommer N, De Toni E, et al. Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients. Eur J Nucl Med Mol Imaging. 2017;44(7):1185-93. doi: 10.1007/s00259-017-3646-z.
  • Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5(1):15. doi: 10.1186/1479-5876-5-15.
  • Pöpperl G, Helmberger T, Münzing W, Schmid R, Jacobs TF, Tatsch K. Selective internal radiation therapy with SIR-Spheres® in patients with nonresectable liver tumors. Cancer Biother Radiopharm. 2005;20(2):200-8. doi: 10.1089/cbr.2005.20.200.
  • Lim L, Gibbs P, Yip D, Shapiro J, Dowling R, Smith D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Intern Med J. 2005;35(4):222-7. doi: 10.1111/j.1445-5994.2005.00789.x.
  • Garin E, Rolland Y, Boucher E, Ardisson V, Laffont S, Boudjema K, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging. 2010;37(3):453-61. doi: 10.1007/s00259-009-1279-6.
  • Yammine K, Kamar F, Nasser J, Tayar C, Ghosn M, Chehade F, et al. Single-Institution Experience with Selective Internal Radiation Therapy (SIRT) for the Treatment of Primary and Secondary Hepatic Tumors. Cureus. 2020;12(4). doi: 10.7759/cureus.7628.
  • Jiao L, Szyszko T, Al-Nahhas A, Tait P, Canelo R, Stamp G, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol. 2007;33(5):597-602. doi: 10.1016/j.ejso.2007.02.021.
  • Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497-507. doi: 10.1053/j.gastro.2010.10.049.
  • Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868-78. doi: 10.1002/hep.24451.
  • Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium‐90 radioembolization for intermediate‐advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013;57(5):1826-37. doi: 10.1002/hep.26014.
  • Hilgard P, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, et al. Radioembolization with yttrium‐90 glass microspheres in hepatocellular carcinoma: European experience on safety and long‐term survival. Hepatology. 2010;52(5):1741-9. doi: 10.1002/hep.23944.
Fuente de los datos: Dialnet